新闻BenzingaLigand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 Est; Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $225.000M-$250.000M vs $288.592M Est Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 Est; Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $225.000M-$250.000M vs $288.592M Est Benzinga 2026.10.29 11:02 (GMT+0) 在Benzinga上打开 其他新闻 摩根士丹利将英伟达目标价从267美元下调至260美元 现代信用卡与摩根大通完成AI代理资金管理概念验证 Visa计划在亚太地区推进稳定币跨境汇款 加密市场提前定价Anthropic,上市前隐含估值较IPO上限高约21% Acala网络将于2027年2月停止出块,用户需在今年年底前迁移资产 Wolfe Research 对 Monster Beverage 启动覆盖,给予“跑赢大盘”评级